Clinical development of an antisense therapy for the treatment of transthyretin-associated polyneuropathy

Amyloid

Volumn 19, Issue SUPPL. 1, 2012, Pages 43-44

  Ackermann, Elizabeth J ^a   Guo, Shuling ^a   Booten, Sheri ^a   Alvarado, Luis ^a   Benson, Merrill ^b   Hughes, Steve ^a   Monia, Brett P ^a  

^a ISIS PHARMACEUTICALS   (United States)

^b INDIANA UNIVERSITY   (United States)

Author keywords

Amyloidosis; Antisense; Transthyretin

Indexed keywords

AMYLOID PROTEIN; ANTISENSE OLIGONUCLEOTIDE; MESSENGER RNA; PLACEBO; PREALBUMIN; RETINOL BINDING PROTEIN 4;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTISENSE THERAPY; CARDIOMYOPATHY; CONFERENCE PAPER; CONTROLLED STUDY; DRUG TOLERANCE; FAMILIAL AMYLOID POLYNEUROPATHY; GENETIC DISORDER; HAPLORHINI; HUMAN; INJECTION SITE PAIN; LIVER TRANSPLANTATION; MOUSE; NONHUMAN; PERIPHERAL NERVE; POINT MUTATION; PRIORITY JOURNAL; PROSTATE TUMOR; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; RODENT; SINGLE DRUG DOSE; SOMNOLENCE; TRANSGENIC MOUSE; VASCULAR AMYLOIDOSIS;

AMYLOID NEUROPATHIES, FAMILIAL; ANIMALS; HUMANS; MICE; MICE, TRANSGENIC; OLIGONUCLEOTIDES, ANTISENSE; PREALBUMIN;

EID: 84861451481     PISSN: 13506129     EISSN: 17442818     Source Type: Journal    
DOI: 10.3109/13506129.2012.673140     Document Type: Conference Paper

References (2)

1. Raal FJ, Santos RD, Blom DJ, Marais AD, Charng MJ, Cromwell WC, Lachmann RH, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet 2010;375:998-1006.
2. Chia S, Dent S, Ellard S, Ellis PM, Vandenberg T, Gelmon K, Powers J, et al. Pha se II trial of OGX-011 in combination with docetaxel in metastatic breast cancer. Clin Cancer Res 2009;15:708-713.